Multivalent live vector vaccine against Clostridium difficile-associated disease
US-10046040-B2 · Aug 14, 2018 · US
Release of growth factors at wound healing stages
US12403179B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12403179-B2 |
| Application number | US-202217675762-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 18, 2022 |
| Priority date | Feb 18, 2021 |
| Publication date | Sep 2, 2025 |
| Grant date | Sep 2, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides collagen-binding agents that can be used to treat wounds, ischemic heart disease, and other conditions. The collagen-binding agents comprise a therapeutic agent, a protease cleavage site, and a collagen-binding domain. The present invention further provides pharmaceutical compositions and biomedical devices comprising the disclosed collagen-binding agents, as well as methods for treating a condition using the collagen-binding agents.
First claim
Opening claim text (preview).
What is claimed: 1. A collagen-binding agent comprising SEQ ID NO:1. 2. A pharmaceutical composition comprising the collagen-binding agent of claim 1 and a pharmaceutically acceptable carrier. 3. A method of treating a condition, the method comprising: administering the collagen-binding agent of claim 1 to a subject in an amount effective to treat the condition, wherein the condition is a wound. 4. The method of claim 3 , wherein the subject is a mammal. 5. A biomedical device comprising a coating that comprises the collagen-binding agent of claim 1 , wherein the biomedical device is a stent and wherein the coating further comprises a biodegradable polymer or a collagen. 6. A method of using the biomedical device of claim 5 to treat a condition, the method comprising: administering the device to a subject having the condition, wherein the condition is a wound.
Assignees
Inventors
Classifications
from bacteria · CPC title
- A61K38/1709Primary
from mammals · CPC title
Macromolecular materials · CPC title
Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)} · CPC title
Fibroblast growth factor [FGF] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12403179B2 cover?
- The present invention provides collagen-binding agents that can be used to treat wounds, ischemic heart disease, and other conditions. The collagen-binding agents comprise a therapeutic agent, a protease cleavage site, and a collagen-binding domain. The present invention further provides pharmaceutical compositions and biomedical devices comprising the disclosed collagen-binding agents, as well…
- Who is the assignee on this patent?
- Univ Arkansas, Nat Univ Corporation Okayama Univ
- What technology area does this patent fall under?
- Primary CPC classification A61K38/1709. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 02 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).